1. Home
  2. CCCC vs XPER Comparison

CCCC vs XPER Comparison

Compare CCCC & XPER Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo C4 Therapeutics Inc.

CCCC

C4 Therapeutics Inc.

HOLD

Current Price

$1.85

Market Cap

194.8M

Sector

Health Care

ML Signal

HOLD

Logo Xperi Inc.

XPER

Xperi Inc.

HOLD

Current Price

$5.42

Market Cap

276.6M

Sector

Technology

ML Signal

HOLD

Company Overview

Basic Information
Metric
CCCC
XPER
Founded
2015
1990
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Semiconductors
Sector
Health Care
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
194.8M
276.6M
IPO Year
2020
2003

Fundamental Metrics

Financial Performance
Metric
CCCC
XPER
Price
$1.85
$5.42
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
5
2
Target Price
$7.25
$11.00
AVG Volume (30 Days)
1.5M
389.4K
Earning Date
02-26-2026
02-25-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
0.15
Revenue
$30,108,000.00
$453,960,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$5.69
P/E Ratio
N/A
$33.32
Revenue Growth
N/A
N/A
52 Week Low
$1.09
$5.09
52 Week High
$3.72
$9.59

Technical Indicators

Market Signals
Indicator
CCCC
XPER
Relative Strength Index (RSI) 37.04 34.48
Support Level $1.69 $5.09
Resistance Level $2.04 $5.80
Average True Range (ATR) 0.12 0.22
MACD -0.03 -0.09
Stochastic Oscillator 14.80 14.69

Price Performance

Historical Comparison
CCCC
XPER

About CCCC C4 Therapeutics Inc.

C4 Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to create a new generation of medicines that transforms patients' lives. The Company is progressing targeted oncology programs through clinical studies and leveraging its TORPEDO platform to efficiently design and optimize small-molecule medicines to address difficult-to-treat diseases. Its degrader medicines are designed to harness the body's natural protein recycling system to rapidly degrade disease-causing proteins, offering the potential to overcome drug resistance, and drug undruggable targets and improve patient outcomes. Its pipeline is Cemsidomide, CFT1946, and CFT8919.

About XPER Xperi Inc.

Xperi Inc is a consumer and entertainment technology company. Its offering comprises a portfolio of software and services. The company creates extraordinary experiences at home and on the go for millions of consumers around the world, enabling audiences to connect with content in a more intelligent, immersive, and personal way. Its business is divided into four categories based on the products delivered and customers served: Pay-TV, Consumer Electronics, Connected Car, and Platform Solutions. It generates the majority of its revenue from the Consumer Electronics segment. Its also have sales in Japan, Europe and Middle East, China, South Korea, Latin America, and Others.

Share on Social Networks: